Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and practices. EXTON, Pa., June 7, 2023 /PRNewswire/ — Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according…